Finanzen von Bioatla Inc (BCAB)BCABBioatla Inc

Evaluating the bottom line, Bioatla Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 3.49%, while the net margin is 6.95%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BCAB converts its operational activities into shareholder value.

In the context of the broader market, BCAB competes directly with industry leaders such as CHGA and CRIS. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, BCAB's gross margin of 100.00% stands against CHGA's N/A and CRIS's N/A. Such benchmarking helps identify whether Bioatla Inc is trading at a premium or discount relative to its financial performance.

Bioatla has shown a troubling financial trajectory, with total revenue of $0 for multiple quarters and a net income loss of -$14,884,000 in Q4 2024. The gross margin fluctuates, but recent quarters show a gross profit of $6,500,000 in Q2 2026, indicating some operational recovery.